Loading
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Previous close
$62.06
+$1.29 · +2.12%
Regular session · ET · Market data may be delayed.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Day range
Current $62.06
52-week range
Current $62.06
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
50
Mixed
Risk
53
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Day range
Current $62.06
52-week range
Current $62.06
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 170.64M USD | 96.67M USD | 69.26M USD | 33.44M USD | 25.17M USD |
| Selling, general, and administrative | 65.38M USD | 33.05M USD | 21.86M USD | 14.04M USD | 5.76M USD |
| Operating expenses | 236.02M USD | 129.72M USD | 91.13M USD | 47.48M USD | 30.93M USD |
| Interest income | 27.76M USD | 21.29M USD | 14.8M USD | 709K USD | 14K USD |
| Interest expense | 3.61M USD | 572K USD | — | — | 2.16M USD |
| Depreciation and amortization | 281K USD | 156K USD | 100K USD | 89K USD | 32K USD |
| Operating income | −236.02M USD | −129.72M USD | −91.13M USD | −47.48M USD | −30.93M USD |
| Net income | −212.18M USD | −109.36M USD | −76.43M USD | −46.83M USD | −35.97M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$106
70.80% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 30, 2022 | 1:10 | — | — |
Effective Dec 30, 2022
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI76.65M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM45.26M0.06%78.27B USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI44.33M0.45%9.87B USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF29.26M0.03%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO15.9M0.12%13.97B USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS14.53M0.04%33.87B USD0.31%$78.35+0.32%
iShares Biotechnology ETFIBB13.35M0.13%10.28B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO12.79M0.07%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
